Leadership: Accomplished. Focused. Passionate.
The successful launch of a commercial-stage pharmaceutical company in the U.S. requires the guidance of seasoned industry executives with unwavering commitment to creating meaningful, durable value for all stakeholders - especially patients. The Soleva leadership team is dedicated to ensuring that vital oncology supportive care products are more accessible to all those whose lives will improve as a direct result of increased access to these treatments.
Soleva executive management has well over 50 years of collective experience in senior biopharma commercial and clinical roles. The management team has developed, implemented and executed strategic and tactical plans for more than 30 leading Rx oncology brands in the U.S. - including several successful new product launches. Soleva's advisors are highly accomplished key opinion and thought leaders with unparalleled expertise in multiple areas of oncology supportive care..
Advisors
Stephen T. Sonis, DMD. DMSc
Steve Sonis is a senior surgeon at Brigham and Women’s Hospital specializing in oral medicine, and is a Clinical Professor of Oral Medicine at the Harvard School of Dental Medicine. Dr. Sonis is also Founder, Partner and Chief Scientific Officer of Biomodels LLC, a preclinical contract research organization (CRO) that conducts predictive and highly translational studies for biopharmaceutical companies in the areas of inflammatory diseases, cancer, cancer supportive care, and pulmonary diseases. He is a world-renowned expert in epithelial injury associated with cancer therapy. His clinical interests include oral mucosal diseases and regimen-related toxicities of cancer therapy. His development of predictive animal models has enabled the investigation of the biological basis of cancer regimen-related epithelial injury and has catalyzed the development of potential therapies. He is the former President of Triad, a not-for-profit company which focused on the adverse health and economic outcomes of cancer treatment toxicities, and serves as a special government employee of the FDA. He has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He holds several patents and is the author of more than 275 original publications, reviews, and chapters and is completing his eleventh book. He obtained degrees from Tufts and Harvard and completed his post-doctoral education (tumor immunology) at Oxford, where he was a Knox Fellow. He is board certified in oral medicine.
David P. Nowotnik, Ph.D.
David Nowotnik has over 40 years experience in pharmaceutical R&D, quality systems, and regulatory affairs. Dr. Nowtnik has served in senior capacities at top global pharmaceutical companies and other leading multinationals, including Tate & Lyle and Aspro-Nicholas. Most recently, he has served as Senior Vice President of Research and Development of Abeona Therapeutics Inc. formerly known as PlasmaTech Biopharmaceuticals, Inc. and Access Pharmaceuticals, and as a R&D Consultant, to Abeona, PlasmaTech and Access, since January 2003. He joined Access in 1998 as Vice President, Research and Development. From 1994 to 1998, he was Senior Director of Product Development at Guilford Pharmaceuticals, responsible for a team of scientists developing polymeric controlled-release drug delivery systems. Prior to Guilford, he was with Bristol-Myers Squibb researching and developing technetium radio pharmaceuticals and MRI contrast agents, and at Amersham International leading the project which resulted in the discovery and development of Ceretec. Dr. Nowotnik received his PhD in Organic Chemistry from University of London.